The 10 Most Influential Leaders in MedTech Companies 2020 September 2020

VOL 09 | ISSUE 10 | 2020

+

Insight Tech Florence Huckert

Goliath

Technologies

MONITORING AND

Tech View Ensuring Healthcare Equity

Thomas

TROUBLESHOOTING

Charlton

END-USER EXPERIENCE

CEO & CHAIRMAN

THE 10 MOST Influential Leaders in

Med Companies 2020

Editor’s Desk

T Serving to Humanity

A real advancement consists vision for all

he deadly coronavirus outbreak in the Wuhan, now termed as COVID-19, and its quick spread to the world, endangers thousands of lives. The event has catalysed the development of coronavirus vaccines. In the biotech industry, both pharmaceutical companies and research organisations are using their potential to develop coronavirus vaccines or antivirals for treating the coronavirus infection.

Medicine is one of the most reputed and collaborative disciplines, and there was an individual Edward Jenner without contributions of his medical care today would be very different. In 1796, British surgeon and naturalist Edward Jenner was the one who developed the first vaccine, the vaccine of smallpox. Jenner was motivated to develop the practice of vaccination after observing that milkmaids who infected by cowpox never developed smallpox. He injected the son of his gardener with the cowpox, and in the results the boy failed to catch smallpox after being exposed repetitively to infected smallpox material. This was the millstone in the field of immunology and the first vaccine as well.

Today the definition of medical advancements has changed as medical technology, or “medtech”, comprises a wide range of healthcare products and is used to treat diseases, save lives or transform the health of individuals suffering from a varied range of conditions. In its many forms, medical technology is already analysing, monitoring and handling virtually every disease or condition that affects humans. At present time, medical technology

includes medical appliances, wearable and vitro diagnostic medical devices.

So, in this edition, ‘The 10 Most Influential Leaders in MedTech Companies 2020’ Insights Success has shortlisted business leaders from Medical and Healthcare industry who are improving the quality of healthcare and visioning to avail advance medical devices, information technology, biotech, and healthcare services.

Also, while flipping the pages, don’t forget to go through the articles and CXOs written by our in-house editorial team and industry experts respectively.

rohit.chaturvedi@insightssuccess.com

COVER STORY

10

Goliath Technologies

ARTICLE

Monitoring & Troubleshooting End-User Experience

40 Ensuring Healthcare Equity

26

Insight Tech Florence Huckert

CXO

Tech View

CONTENTS

20 Abionic SA

Revolutionizing the World of In Vitro Diagnostics

22

Allscripts

Building Open & Connected Communities of Health

30 CereSoft Energizing Healthcare Cash Flow

32

ClinCapture

36

A Sweeping Wave of Big Data Innovation in the Pharmaceutical Industry

CMIC Inc.

Leading Treasure in Healthcare Industry Especially in Pharmaceutical Sector

44

48 Triox Nano

Metrendalytics

Combining Knowledge and Technology to Bring EfďŹ ciency in Business

Pioneers in point of care programmable medicine! presenting the next healthcare revolution!

Editor-in-Chief Sumita Sarkar Managing Editor Anish Miller

Executive Editor

Assistant Editors

Rohit Chaturvedi

Jenny Fernandes

Visualizer

Art & Design Director

Associate Designer

David King

Asha Bange

Kartik Balapurkar

Co-designer Kushagra Gupta

Senior Sales Manager

Business Development Manager

Kshitij S

Andy Mitter

Marketing Manager

Sales Executives

John Matthew

David, Martin, Avinash

Technical Head

Business Development Executives

Jacob Smile

Steve, Joe, Aidan, Anup

Technical Specialist Aditya

Digital Marketing Manager Marry D'Souza

SME-SMO Executive Amol Wadekar

Research Analyst Frank Adams

Database Management Stella Andrew

Circulation Manager Robert Brown

Technology Consultant David Stokes

sales@insightssuccess.com September, 2020

Follow us on :

www.facebook.com/insightssuccess/

www.twitter.com/insightssuccess

We are also available on : Copyright Š 2020 Insights Success, All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights Success.

Reprint rights remain solely with Insights Success.

Company Name

Management

Brief Goliath Technologies offers end user experience monitoring and troubleshooting software, with embedded intelligence and automation, that enables IT pros to anticipate, troubleshoot, and document performance issues regardless of where workloads, applications, or users are located.

Abionic, an in vitro diagnostics (IVD) company, is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

Goliath Technologies goliathtechnologies.com

Thomas Charlton CEO

Abionic abionic.com

Nicolas Durand Founder and CEO

Allscripts allscripts.com

Paul Black CEO

Allscripts knows providing excellent healthcare while striving to achieve business and operational goals. It is embracing all aspects of the healthcare industry while thriving within its constant evolution.

CereSoft ceresoft.com

Hsing-Hen Chen CEO

CereSoft is a healthcare revenue cycle management services company based in Silver Spring, Maryland. It processes millions of healthcare transactions daily for some of the most high profile healthcare providers and financial institutions in the United States.

ClinCapture clincapture.com

Scott Weidley CEO

Fundamentor is an innovative web application that enhances the Quantitative, Verbal, Data inference and Creative thinking aptitude in school students.

CMIC cmicgroup.com

Jenny Lin, Chief Operating Officer & Board Member

CMIC, Inc. leading CRO (Contract Research Organization) and a provider specialized in bioanalytical services, whose cuttingedge capabilities and sophisticated expertise in various aspects helped it achieve a greater stature in the business.

Metrendalytics metrendalytics.com

Jan Miotto President

Metrendalytics Consulting, focused on helping companies develop highly customized and flexible business intelligence solutions.

Roy Farfara MD, Founder & CTO

Triox Nano’s management describes its impeccable journey to become the first biotech company to develop a modular programmed drug delivery platform.

Bart Carlson CEO and Chief Patient Advocate

Azuba is an independent, cloud-based health-information platform, which enables patients, providers and payers to securely use comprehensive health information - anytime, anywhere - leading to improved health outcomes.

Thomas Smeenk CEO

Hemostemix is a clinical-stage biotechnology company focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases.

Triox Nano f6s.com

Azuba Corporation azuba.com

Hemostemix hemostemix.com

COVER STORY

GOLIATH TECHNOLOGIES Monitoring and Troubleshooting End-User Experience

Thomas Charlton CEO & CHAIRMAN

Goliath offers the ability to continually test application availability delivered via Citrix or VMware Horizon from remote locations. The technology then proactively alerts Health IT if an application or the delivery infrastructure is down or slows so you can resolve before medical staff are impacted.

The 10 Most In luential Leaders in MedTech Companies, 2020

W

ith the intent of offering end-user experience monitoring and troubleshooting software, with embedded intelligence and automation, that enables IT pros to anticipate, troubleshoot, and document performance issues regardless of where IT workloads, applications, or users are located, Goliath Technologies came into existence. The organization believes, most organization simply don't have enough time, tools, and staff to troubleshoot every end-user ticket or complaint. This is where Goliath comes in. With its embedded intelligence and automation, the company proactively look for events, conditions and failure points that precipitate end user experience issues. Goliath Technologies also provides broad and deep visibility across the delivery infrastructure (Citrix or VMware Horizon), hypervisor, servers, operating systems and applications to quickly identify where end-user performance problems occur and what is causing them.

As the Chairman and CEO, Thomas Charlton is responsible for the strategic direction and global expansion of Goliath Technologies.

He has most recently orchestrated the turnaround at PHD Virtual as Chairman and CEO. After multiple CEO's, the majority shareholder, Insight Venture Partners, brought in Mr. Charlton from Shunra Software, another portfolio company. Seven record quarters of growth followed from Q3 2010 to Q1 2012 driven by the acquisition of four new customers per business day. During this time, Insight Venture Partners and a new investor, Citrix Systems, provided additional equity financing. PHD Virtual was acquired by Unitrends in 2013.

In an interview with Insights Success, Thomas Charlton, the CEO and Chairman of Goliath Technologies, has shared key insights of the struggles and journey of the organization.

Below are the highlights of the interview between Insights Success and Thomas Charlton; Kindly take us through your journey on becoming a proficient med tech leader.

I began my career in healthcare working for US Surgical.

We offered stapling instruments that dramatically shortened the time it took to complete a surgical procedure which improved patient outcomes while lowering costs. As my career progressed, I moved out West to San Francisco in the middle of the dot-com boom. For the first time I was

exposed to the technology industry, and I began to read every book I could on the market and the major players. It appeared an exciting and inviting meritocracy. People didn't care about your level of education, background, or anything subjective. The key to advancing was performance. I left my executive level position in US Surgical and took a position as a regional manager at Legato Systems. After a year, I left Legato Systems for the VP of Sales position at Tidal Software and eighteen months later I was appointed CEO of that same company. I was CEO of five more venture-backed companies, after which I founded Goliath Technologies. Now I have merged my healthcare and software knowledge by adapting our technology for the healthcare marketplace to specifically focus on improving end user and clinician experiences related to the major EHR applications Epic, MEDITECH, Allscripts, and Cerner.

Today, we are known as the Health IT standard by our clients and competitors.

How do you diversify your organization's offerings to entice the target audience?

Diversification is certainly one way to entice a target audience. While our technology is decidedly cross vertical, our healthcare clients require purpose-built technology to solve very specific issues faced by today's Health IT departments. An enterprise IT department will have twice the budget and people to support the same number of users as the same department in a health system. And, in Health IT, patient care is ultimately in the balance if IT systems don't perform optimally. In the products we developed for Health IT we made very deliberate decisions to add features that help our Health IT professionals address challenges that are unique to their situation. Specifically, we developed integration and support for the clinical and business applications that are critical to their end users along with automation and embedded intelligence that has the net effect of adding three full-time employees to their staff.

Have you drawn professional inspiration from other business leaders? Tell us about someone who has inspired you.

I was very fortunate in this regard. I had three men who both inspired and taught me how to lead an organization.

First, my father, who was an accomplished business leader himself in the steel and manufacturing industry. He imbued me with the foundational personality traits that every leader should possess. Then, I met Carlos Babini at US Surgical

who, by example and teaching, showed me how to manage teams and practice leadership. Carlos was especially effective at turning around failing divisions for the company. He was effectively the go-to executive that was put in charge when parts of the business were not performing. He educated me, over years, on how to lead teams through a crisis in leadership and back to acceptable business performance. Finally, Lacy Edwards, Chairman of the Board at Tidal Software, taught me how to be a CEO of a venture-backed software company. He offered me very specific direction on tactics, strategy, and code of conduct.

These gentlemen were all equal parts demanding and instructional. Each of these men, all very accomplished, took time that could have been spent elsewhere and shared it with me. For that I am both fortunate and eternally grateful.

What values are important to you as a business leader?

I think a good business leader needs to operate with integrity, empathy, and courage. Most tech firms, especially software, are successful because of the sum contributions of their people. Without these core values, I don't think you can effectively build or lead a great team in a sustainable fashion.

How do you achieve work-life balance?

I think stress is created as a result of people's unrealistic expectations of and desire to achieve, so called work-life balance. If creating an even balance between one's personal, professional, and financial goals is the objective then that is one thing. However, if one desires to achieve something great, above average, and certainly if you want to lead your own company, then the relative emphasis and corresponding time spent in these three areas is going to change over time. Read a story about the leaders of any great tech company, whether it is HP, Oracle, Microsoft, Apple, or Amazon, and it is manifestly evident that prioritization across these three life areas was not equal and therefore out of balance at certain times. But their goal wasn't balance it was achievement.

What was your life changing event/incident that changed your life?

There were a number of them in my personal and business journeys. One, that I reflect upon often, occurred when I was going to visit a friend of mine who was attending an

Ivy League University. It was homecoming at the university and I made the drive with his father to visit. The conversation turned to careers during the drive. He suggested, given that I was only attending a community college, I finish my two years and then build the lawn mowing business which I had through high school and college. His opinion was that without an Ivy League education I was relegated to a career of tending to the lawns of more educated men. I was more than mildly upset and insulted at the time but didn't have the benefit of experience yet to know that people will attempt to set expectations for you based on their own prejudices, insecurities, and limitations, not your best interest or potential. In the United States, we have no caste system, royal family, or contrived subjective impediments that seek to prevent certain groups of people from advancing their position. In this country what you expect of yourself, and the desire to achieve, are the only limiting factors to success.

How necessary is it to align business with technology and what are its outcomes?

It is critical because technology has no value without that alignment. Successful technology companies enable better business outcomes. In fact, many technologies and technology companies fail do so because there isn't a business benefit, or large enough one, to create sustained demand for the product or service.

What are your future endeavors/objectives and where do you see the medical industry in the near future?

This is a question that is difficult to answer in today's environment. Emergency room visits have almost evaporated and that isn't revenue health systems will get back. At the same time, elective surgeries have been suspended. It is a gross understatement to say this is a challenging time for health systems. Based on conversations with our health system clients, we see an acceleration towards technical solutions that will enable the provisioning of healthcare remotely. Telehealth is one such example. Health systems that had one hundred telehealth visits a few months ago are now seeing thousands. This is a real opportunity for tech companies to serve ongoing patient care by advancing their remote enablement technology. As with any crisis, there will be opportunity created for those who have the vision, awareness, and capability to act.

“ Once we establish the right market and product, our goal is to focus on the team.

“

Goliath Technologies' software is available through the Epic App Orchard site for any Epic customer.

Goliath Technologies, the standard in Health IT, provides an end-to-end view that enables Health IT to bring end-user experience, delivery infrastructure, and EHR application metrics together to anticipate, troubleshoot, and document issues within the Clinical Virtual Workspace.

What advice would you like to give to the emerging tech leaders?

This is a broad question given the number of areas on which to oer advice. From a purely business perspective there are three key pillars that support a successful company. They are marketplace, technology, and business execution. The ďŹ rst is most important because we don't have the power to change it where, with time and capital, you can impact the other two pillars of success. In my years with venture capital, I would say most companies failed because there was either no market or not a large enough market for the technology to allow sustained growth.

People tend to become enamored with technology and business plans. Neither of those will matter without a market pull for the technology. I look for known markets with incumbent competitors where I can introduce a

technology that has a price or performance advantage that can be utilized by companies that are underserved by the current solutions.

The 10 Most In luential Leaders in MedTech Companies, 2020

Abionic SA Dr. Nicolas Durand Founder & CEO

Revolutionizing the World of In Vitro Diagnostics Committed to Medical Innovation

I

n 2009, more than 100 million Europeans suffered from allergies. Ironically, the sharp rise in allergyrelated conditions of recent decades can be traced back to improved hygiene. European public health systems have identified this surge as one of the main factors that put pressure on their infrastructure.

In the biomedical field, the demand for reliable, fast, and inexpensive products to diagnose allergies continued to grow. With this finding, Dr. Nicolas Durand and Dr. Iwan Märki launched Abionic.

They developed an advanced diagnostic platform that can quickly obtain a patient’s personalized allergy profile. This in vitro test, which has been designed to be simple, reliable and cost-efficient, is an alternative to expensive blood tests performed in laboratories that are currently used to identify allergies.

Since its establishment, Abionic has used these highly advanced technologies with a vision to improve healthcare and enhance the wellbeing of the patient.

20 | September 2020

In Vitro Diagnostics (IVDs) are medical devices and accessories used to perform tests on samples, e.g., blood, urine and tissue that have been taken from the human body, to detect infections, diagnose medical conditions, and prevent diseases.

Abionic is committed to revolutionize the world of in vitro diagnostics with rapid universal point-of-care solutions. It develops and produces tests that have proven to be game-changers in each of their respective markets. Furthermore, they allow access to lab-quality blood analysis even where there is limited infrastructure in place.

Abionic utilizes the most advanced technology to supply healthcare professionals with a novel diagnostic tool. Its products, the abioSCOPE (the reader), abioGUIDE (the application for smartphones and tablets), and the tests containing nanofluidic sensors have been developed and are assembled by the company in Switzerland.

A Dynamic Young Leader In 2010, Nicolas Durand, Founder and CEO of Abionic was fresh out of EPFL with a Ph.D. in nanotechnology when he launched Abionic in collaboration with Iwan Märki. The firm was set up to build on Durand’s doctoral www.insightssuccess.com

research, which aimed to develop a nanofluid-based system that could speed up blood test diagnostics.

Nicolas has also been involved in the development of resonating biosensors at Carnegie Mellon University (USA).

He is the winner of the 2006 Omega Award as well as more than 20 entrepreneurial awards, including the 2010 Young Entrepreneur Award.

Nicolas has earned a private pilot’s license and was an astronaut candidate for the European Space

We use the most advanced nanotechnology to supply healthcare professionals with a novel diagnostic tool and, thereby, bringing the treatment closer to the patient. www.insightssuccess.com

Agency, on top of being an active infantry officer in the Swiss army.

Rapid and Reliable Point-of-care Solutions Abionic takes established and trusted diagnostic principles to the point of care so patients can get their results immediately. Recently, the company announced the CE marking of the world’s most rapid test for the early diagnosis of sepsis and treatment management.

With an annual death toll of more than 6,000,000, sepsis kills more people than breast cancer, prostate cancer, and AIDS combined. Many of these deaths could have been avoided if the condition had been diagnosed and treated earlier.

Abionic’s PSP test, which is an aid at diagnosis patients at risk of developing sepsis in real-time has the remarkable potential to save millions of lives.

The Pivotal Movement Abionic has had its sights set on international expansion since 2012, when it obtained ISO 13485 certification, an important mark of credibility and a requirement to sell medical devices in the European Union.

The same year, the firm attracted its first investors with a Series ‘A’ financing round that brought CHF 3.5 million in cash. Two years later, the first healthcare professionals – mainly doctors – contacted the company to test their technology.

promised and did so at the first clinical trials which followed. That was closely followed by a Series ‘B’ financing round with Swiss and European entrepreneurs. By then, Abionic’s prototype had become a viable product; in 2016, the firm began demonstrating commercial traction by selling its devices to the market.

Recently, the Series ‘C’ round was closed to secure financing of clinical impact studies and the development of further tests.

Today, the entire production chain is located in Switzerland and based in Lausanne. It has the capacity to produce up to one million test kits per year.

International Expansion Abionic envisions revolutionizing the world of in vitro diagnostics with rapid universal point-of-care solutions powered with disruptive nanotechnology. To demonstrate the test’s medical and economic impact, the company currently carries out a large-scale clinical trial of its sepsis tests in fourteen sites across Europe.

Abionic aims to expand its business internationally and is working on the development of further innovative and impactful tests.

Abionic had to prove that its nanotechnology could perform as

September 2020 | 21

The 10 Most In luential Leaders in MedTech Companies, 2020

Paul Black CEO & Board Member

llscripts is a leader in healthcare information technology with a 30-year history of excellence.

The company has a vision to build open and connected communities of health that advance clinical, financial and operational results.

A

A Veteran Leader Paul Black currently serves as a board member and the CEO of Allscripts. Paul leads the company in its commitment to build open, connected communities of health.

Its innovative solutions connect people, places and data across its vision of an Open, Connected Community of Health™. This connectivity empowers caregivers to make better decisions and deliver better care for healthier populations.

Prior to joining Allscripts in 2012, Paul spent more than 13 years with Cerner Corporation in various executive positions and retired as its CEO in 2007. During his tenure, he helped build the company into a market leader in healthcare information technology with more than $1.5 billion in annual revenue.

Allscripts creates tools that address virtually every aspect of population health, an each of these tools facilitates real-time analysis and action. They enable healthcare organizations to analyze and act – right at the point of care – to empower change, improve health, and reduce costs.

CareInMotion™ is the company’s comprehensive population health platform. It brings together care coordination, patient engagement, connectivity, data aggregation, and analytics at the point of care.

22 | September 2020

Paul also spent 12 years with IBM Corporation in a variety of leadership positions in sales, product marketing, and professional services. He has served on the boards of several private companies and nonprofit organizations involved in healthcare information technology, healthcare services, and consumer Internet marketing.

He is currently the immediate past chairman and an officer of Truman Medical Centers, a 400-bed safety net academic hospital in Kansas City, MO. Paul holds a

www.insightssuccess.com

“

“

Bachelor of Science degree from Iowa State University and a Master of Business Administration degree from the University of Iowa.

Committed to Client Success Allscripts is the original open, connected health platform. Thousands of the top hospitals, health systems, physician’s practices, and healthcare facilities use the company’s EHR, financial management, and population health management solutions.

community through open and interoperable solutions that empower communication, collaboration, and coordination for better outcomes. Ÿ Innovating to improve the practice of medicine and the process of care delivery.

Superior Patient Engagement Allscripts believes that healthcare doesn’t begin and end with just providers and patients, and it is the only company that brings all healthcare stakeholders together.

By collaborating with payers, health plans and programs, pharmaceutical and life sciences companies, and employers, Allscripts has gained a wider view of the care process. It uses that perspective to create innovative tools that lower costs and improve care.

Allscripts offers the industry’s only vendor-agnostic patient engagement platform. With the advantage of open access across the care community, providers can communicate effectively and engage patients directly, creating game-changing improvements in patient outcomes and operational performance.

Allscripts believes that the patient is at the center of everything it does. Modern healthcare consumers understand the benefits of engagement, and they expect to be active participants in their own care. The organization partners with providers to deliver an improved patient experience where individuals have a greater say in the treatment they receive.

As a true healthcare IT innovator, Allscripts introduced the concept of an open platform connecting all points of the care community over a decade ago in 2007. The organization provides advanced, reliable, client-focused solutions that enable smarter care to be delivered with greater precision. This makes for healthier patients, populations, and communities.

The organization contributes to its clients’ success by:

With Allscripts, healthcare organizations have at their disposal the critical tools required for ongoing communication, effective education, and regular interaction with patients. These tools make it easy for caregivers to engage and quickly respond to consumers while also offering them full, immediate access to their healthcare information.

Strengthening their IT foundation through the most comprehensive and user-friendly clinical and financial solutions available today. Ÿ Providing insights and innovations so they can meet the operational, regulatory and quality demands of today’s - and tomorrow’s - healthcare environment. Ÿ Connecting everyone across the healthcare

Evolving and Overcoming Challenges When Allscripts was founded in 1986, its primary business was repackaging medication for point-of-care distribution. In the 1990s, Allscripts started transforming the doctor’s office with comprehensive practice management and electronic health record (EHR) solutions.

Ÿ

www.insightssuccess.com

September 2020 | 23

Looking to the future of healthcare, Allscripts launched a wholly-owned subsidiary, 2bPrecise, a genomic and precision medicine platform, in 2016. In October 2017, the company acquired Enterprise Information Solutions (EIS), the McKesson Corporation’s hospital and health system IT arm.

This transaction significantly expanded their client base in U.S. hospitals and health systems, and diversified its solutions portfolio.

“

“

To address fragmented care delivery, Allscripts merged with acute-solution leader, Eclipsys in 2010. In 2013, Allscripts took several significant steps to solidify and advance its population health management solutions.

This included the acquisition of dbMotion, a leading supplier of community health solutions, and of Jardogs, the developer of FollowMyHealth, a patient engagement solutions provider.

Today, Allscripts is a team of more than 7,000 devoted to fulling the needs of providers today and creating the health IT architecture of tomorrow.

Allscripts built its latest EHR from the ground-up using human-centered design. This platform is set to transform the way physicians experience and interact with technology, as well as improve provider wellness.

The healthcare IT industry is extremely competitive and Allscripts distinguishes itself by creating tools that facilitate real-time analysis and action. Its solutions enable healthcare organizations to analyze and act – right at the point of care – to empower change, improve health, and reduce costs.

Machine learning capabilities incorporated into the system identify client treatment patterns. It can prepopulate information based on these patterns and deliver preference reminders. By constantly tracking user, organization, and region trends, it creates opportunities for more efficiency.

In addition, the company addresses virtually every aspect of population health. Allscripts provides a comprehensive population health platform, brings together care coordination, and promotes patient engagement, connectivity, data aggregation, and analytics at the point of care.

The power of artificial intelligence reveals information relevant to a patient-provider encounter in real time, and this helps improve the quality and speed of interaction with the patient. Ultimately, this reduces the amount of time spent on documentation, helping address the problems of “EHR fatigue” and physician burnout.

The Future Roadmap Allscripts acknowledges that it is becoming increasingly difficult to retrofit EHRs to take full advantage of new innovations such as the Cloud, artificial intelligence, and mobility. The organization believes that machine learning will be a critical element in the evolution of EHRs.

Allscripts is incorporating EHR-agnostic, precision medicine, and genomic capabilities within providers’ workflows. This will help capture and store genomic data from a range of sources, harmonize clinical knowledge and genomic research to identify relevant information, and then push the resulting insights to the point of care to better determine the most effective regimen for the patient.

24 | September 2020

www.insightssuccess.com

26 | September 2020

www.insightssuccess.com

Insight Tech

www.insightssuccess.com

September 2020 | 27

28 | September 2020

www.insightssuccess.com

The 10 Most In luential Leaders in MedTech Companies, 2020

CereSoft Dr. Hsing-Hen Chen President & CEO

Energizing Healthcare Cash Flow decrease costs by addressing people, process, and technology components across the revenue cycle spectrum.

T

he healthcare sector is in a state of constant flux and institutions are under tremendous pressure to deliver high-quality patient results while also maintaining desired profit margins. They have to balance these requirements while adhering to a growing array of regulatory specifications and other dynamic forces. In this scenario, maintaining financial stability is a challenging but essential task.

Hospitals and healthcare systems are recognized for treating patients and saving lives but every healthcare organization also has an obligation to remain financially viable. Healthcare revenue cycle management plays a crucial role here.

Healthcare revenue cycle management is the financial process that facilities use to control and oversee administrative and clinical functions connected with processing claims, cyclic payments, and income generation. The process includes the identification, management, and collection of patient service revenue.

CereSoft’s Revenue Cycle Transformation works with healthcare providers to help them recognize ways to boost their net income, accelerate cash flow, and

30 | September 2020

Thought Leadership in Healthcare and Technology CereSoft is a technology pioneer and forward-thinking company based in Silver Spring, Maryland. It was founded in 1994 and today has over 200 employees worldwide. CereSoft can handle the revenue cycle needs of both large hospital systems and physician networks.

For over 20 years now, the company has been creating feature-rich, real-time digital exchanges with its clients in the healthcare industry, while demonstrating thought leadership in both healthcare and technology services throughout the United States.

CereSoft’s one-stop solution for healthcare revenue cycle management is spearheaded by its flagship product and web portal, MedAR. MedAR allows users to handle correspondence, financial analysis, denials, underpayments, refunds, dependent claims, reassociations, and other critical online functions within a single system.

MedAR provides complete revenue cycle transformation for medical practices as well. Its financial management On-line Navigation System reduces the time required to process manual posting to billing systems, denial processing days, manual keying of transactions, and the time required to balance.

www.insightssuccess.com

It also allows the provider to view any electronic document with a single touch. CereSoft’s great references, functionality, and ability to complete the paper conversion to EDI processing in less than 24 hours helps clients improve their revenue management and move forward on their innovative journey with notable speed.

CereSoft provides claims presentment to the payer gateway and accepts both ERAs and Paper EOBs for processing. The company matches and balances that information with ACH/EFT payments and paper checks.

CereSoft’s online portal processes both co-pays and patient pays as they are integrated into the CereSoft Desktop Navigation System.

The company provides a SingleTOUCH Methodology under a SingleVIEW.

Anyone with an internet connection, anywhere in the world can access, monitor and work using our cloud-based platform.

This will provide significant cost reductions in the years to come.

www.insightssuccess.com

A Single View Portal with Touch and Feel Design CereSoft is constantly seeking true partnerships. More than 80% of its portal is connected with its users, and the touch-and-feel architecture of the platform is a result of their valuable feedback.

Clients expect a ‘Single View’ platform that can handle both paper and electronic formats, as well as structured and un-structured data in a single application. CereSoft offers a true virtual work desk where every employee has access to a Single View of all financial transactions.

The integration of all fragmented components and document types in one platform allows clients to search, retrieve and view all data and file sources on a single system. This leads to performance characterized by high speed, accuracy, reliability and efficiency.

CereSoft has the finest sales and marketing organization in the country that are not sales-based people; they are consultants that provide problem solving techniques to all their customers and business partners.

Visionary Leadership in an Evolving Industry Dr. Hsing-Hen Chen is President, Founder and CEO of CereSoft.

Dr. Chen has an unusual background for this industry. He has been a fulltime professor in Physics at the University of Maryland for the past 40 years, and started off as an expert in non-linear complex systems that include neural networks, and deep learning AI systems in particular.

This unique background led him into

the business document and process renovation field. Dr. Chen envisioned automating the healthcare RCM process to integrate claim submissions, payment adjustments, cash posting and other necessary business workflows.

He developed an intelligent process to capture business data from structured, semi-structured and even fully un-structured documents, including databases, electronic files, business forms and paper correspondence.

Dr. Chen’s visionary leadership has positioned CereSoft as the company to watch in this fast-evolving industry.

Cutting-Edge Technology and Innovation The CereSoft system is field-proven across both large- and small-scale implementations and it has shown that it is capable of meeting special requirements and adapting to customized business rules.

CereSoft is committed to integrating leading edge technology and innovative payment methods into its flagship Payment Central Platform, which includes features like checks, mobile pay with image recognition technology, document understanding and artificial intelligence.

The company envisions employing robotic process tools and block chain technology to enhance the security and efficiency of its intelligent system.

September 2020 | 31

The 10 Most In luential Leaders in MedTech Companies, 2020

ClinCapture A Sweeping Wave of Big Data Innovation in the Pharmaceutical Industry

A

Few years ago, Mckinsey Global Institute estimated that the application of big-data strategies to improve decision making was capable of generating over $100 billion in value annually across the US health-care systems. This advanced decision making made possible by cloud technology, improved analytical methods was the next horizon of innovation on the block.

Today, this change is sweeping across the healthcare landscape creating value and opening new territories for innovation.

However, in order to benefit from this innovation it is important for companies to optimize this innovation and improve the efficacy of their current research methods and trials simultaneously. This innovation opens up a personalized array of solutions for patients supported by a wide array of tools for physicians, consumers, insurers and regulators.

A large part of this innovation is the role of Big data and it is an opportunity unlike anything we have witnessed before.

Earlier the data generated from clinical trials under controlled environment could be well documented.

However, with the advent of cloud solutions, pharma companies can store data from various sources including patient care, retail stores and caregivers as well. Of course, all of this data must be HIPAA compliant. Applying this data effectively will allow pharmaceutical companies to get an insight into the industry to predict the rise of new patient needs and develop effective drugs to reach new patients and reach greater heights.

32 | September 2020

Todd Weidley Scott Hu man CEO & Co-founder President & CEO

ClinCapture provides a powerful eClinical platform that enables sponsors and CROs to rapidly build and deploy studies, lower clinical trials costs, and streamline data capture processes. Offering a host of private cloud solutions, ClinCapture’s technologies help advance the evaluation and development of drugs, biologics, and devices that demonstrate promise for the diagnosis and/or treatment of a wide range of diseases or medical conditions.

By bringing greater efficiency and accuracy into clinical trials, ClinCapture serves the mantra, “Software that saves lives!”

A vision - the Turning Point CEO Scott Weidley joined the ClinCapture team at a pivotal time in the company’s history. The company had recently built Electronic Data Capture (EDC) software, but was also a

www.insightssuccess.com

professional services business. Weidley saw the value of technology in the clinical trials space, and felt that customers were seeking solutions – not services. From this vision, the Captivate eClinical platform was born.

“Scott is the Marc Benioff of EDC,” Ale Gicqueau, ClinCapture founder, was quoted as saying at the time.

History seems to be proving him right, as ClinCapture is now a leading provider of eClinical software solutions.

help advance the evaluation and development of drugs, biologics, and devices by bringing increased efficiency and accuracy into the clinical trials process, thereby allowing pharmaceutical, biotechnology, and diagnostic companies to bring products to the market faster and at a lower cost.

Ultimately, these products may be lifesaving; this is the story behind the mantra of the company, “Software that saves lives!” ClinCapture’s customers are creating medical advancements, some of which may have life-saving applications.

A Leading Innovator From the beginning, ClinCapture has set out to be different than what the industry is used to. Its competitive and technologically-advanced product is setting new EDC industry standards, giving customers a higher quality, more affordable EDC alternative to established industry leaders. For example, Electronic Data Capture (EDC) with Medical Coding integrates a user-friendly interface that was built on the same modern framework as Facebook, Instagram, and Netflix and includes a free build tool, and free training and support. Additionally, it is HIPAA, CFR 21 Part 11, and GDPR compliant and the platform includes Electronic Clinical Outcomes Assessments (eCOA) / Patient Reported Outcomes (ePRO) as well as Randomization options for customers.

The company has pushed the limits with both the brand and the product alike. It believes in providing innovative and high-quality Electronic Data Capture (EDC) product at a fraction of the cost of its leading competitors. Its eClinical solutions

www.insightssuccess.com

Our primary goal is to continue to provide our customers with the highest-quality eClinical solutions at the lowest price.

An Upcoming Bright Future There are two or three big companies in the eClinical space and ClinCapture is committed to being on top in terms of quality with these companies. It has stayed true to its brand and its highquality product, which is increasingly gaining popularity with clinical data managers in the industry. When asked about the future prospects of the company, Scott said, “From big 3 EDC to the gold standard in EDC? We are on our way!”

He also added, “ClinCapture is growing at a high velocity as we continuously introduce new products.

Our primary goal is to continue to provide our customers with the highest-quality eClinical solutions at the lowest price.” His statement highlights a rapid advancement in the industry.

According to the Mckinsey Global Institute study, there are various segments in the pharmaceutical industry which are experiencing a rapid growth. One such segment is biopharmaceuticals. According to the study, the rates of growth for biopharmaceuticals is near 8% annually and it is almost double that of conventional pharmaceutical solutions.

In order to tap the growing potential and demand in the pharmaceutical industry, ClinCapture adopts a simple approach to innovation. To summarize it, Scott said, “Data is what makes it work. We love our customers. We love data managers!”

September 2020 | 33

The 10 Most In luential Leaders in MedTech Companies, 2020

CMIC Inc. Leading Treasure in Healthcare Industry Especially in Pharmaceutical Sector

P

harmaceutical sector is blooming at subsequently than ever being imagined.

And only few companies proved themselves worthy of it. Meet, a CMIC, Inc. leading CRO (Contract Research Organization) and a provider specialized in bioanalytical services, whose cutting-edge capabilities and sophisticated expertise in various aspects helped it achieve a greater stature in the business. Its bioanalytical services are in support of TK/PK/PD Biomarker studies for pre-clinical and clinical developments. It firmly focuses and holds expertise in bioanalytical method development, method validation/qualification and study sample analysis for small, large molecules and Oligonucleotide. The “CMIC” name originally stood for “Current Medical Information Center”, and the company remains committed to the advancement of medicines and healthcare revolution. As a strategic drug development partner, CMIC helps sponsors to overcome challenges in bioanalysis with expertise, rapid data turn-around-time, and high-quality customer services.

The company states its core values intercepted through, W & 3C; WELLBEING: Fully Live Every Moment Challenge: Liberate opportunity by changing our vantage point Change: Transform without seeking refuge in conventional wisdom Communication: Proactively reach out to sponsors, people and society

Ÿ Ÿ Ÿ Ÿ

The Story behind CMIC CMIC Inc. originated from CMIC Group, which is the very first and largest Contract Research Organization (CRO) in Japan. Contract research organizations (CROs) have become an integral part of drug discovery and development to support sponsors research needs, expedite timelines and provide an extension of technical and scientific support. CMIC has worked with the top 10 global pharma companies and has been involved in and supported more than 80% of new drug development in Japan.

CMIC, Inc. was established as a strategic cornerstone for CMIC Group’s North America growth. It has the vision to provide a solution service as “Pharmaceutical Value Creator” (PVC) that encompasses an entire value-chain of pharmaceutical companies. The company has been the top bioanalysis CRO in oligonucleotide therapeutics (Oligo) development for nearly a decade with strong proven expertise. It also o ers 30+ years of experience in conventional & small molecule and are also significantly expanding its capabilities in large molecule and biomarker Bioanalysis.

On account being di erent from other companies, it is leading bioanalysis CRO in oligonucleotide therapeutics (Oligo) as well as very flexible and agile with quick turn-around time on all services o ered, which is not possible by large CROs. In addition, CMIC, Inc. together with the rest of CMIC Group has significant scientific publications and whitepapers and had been the integrated players f supporting various drug development e orts.

36 | September 2020

www.insightssuccess.com

Jenny Lin Chief Operating OfďŹ cer & Board Member

www.insightssuccess.com

September 2020 | 37

38 | September 2020

www.insightssuccess.com

“Our vision is to advance the innovation of products and solutions that will empower people worldwide to achieve greater health and well-being.”

A Glimpse into Jenny’s Life Jenny Lin, Chief Operating O cer and Board Member. She holds 26 years of executive/lab management experience in bioanalytical and analytical laboratory operations in support of drug discovery, pre-clinical and clinical drug development. Moreover, she is proficient in GLP, GMP, GCP, OECD, ICH and 21 CFR part 11 regulations and in business strategic planning and execution. Her expertise includes building organizational quality system, sta training, bioanalytical/analytical method development/validation, bioanalytical sample analysis, analytical development for CMC submission, chromatography purification, stability studies, reference standard certification, QC support for GMP manufacture.

She has been also a selected member for Global Bioanalysis Consortium (GBC) making recommendations for global Bioanalysis harmonization. She serves as editorial board member for peer reviewed journal and chair for international conferences.

Besides, she is an author and co-author for approximately 40 publications, white papers and presentations and is the inventor of 7 issued US patents. Jenny earned her BS in Analytical Chemistry at Peking University and her MS in Medicinal Chemistry at University of Connecticut. She is a member of the American Society of Mass Spectrometry (ASMS), American Association of Pharmaceutical Scientists (AAPS), American Chemical Society (ACS), National Association of Professional Woman (NAPW) and Global CRO Council (GCC).

Future of CMIC CMIC and the CREED as corporate philosophy, consists of Wellbeing, Challenge, and Communication (W&3Cs). The company has been applying these items to continuously evolve itself in line with market changes, and will do so in the future.

Moreover, by further expanding from the current “Pharmaceutical Value Creator” (PVC) business model, the company has an aspiration to become a “Personal Healthcare Value Creator” (PHVC) to contribute for and to address to the up-coming personalized medicine and individual patient quality of life.

www.insightssuccess.com

September 2020 | 39

W

e all bargain for a little more, everybody wants a better life, we all know what success sounds like, or is there something more to life?

Everybody loves a hero. During this pandemic period of Coronavirus, healthcare workers are our real heroes. They are the ones who inspire us to hold on for a little longer.

While the world was at a stop, they were the ones risking their lives to save ours and they continue to do so. Will we really achieve our dreams if there is no healthcare system in any country? This article will evaluate the importance of healthcare leaders in society.

ENSU HEALTH EQU

Any crisis brings opportunities for improvement and change. The current situation of Covid-19 makes us realize the importance of the healthcare industry. This is an opportunity for countries to increase expenditure on the much-needed healthcare infrastructure. Conserving and ensuring the well-being of the healthcare workforce is the need of the hour. Even before this pandemic, the healthcare system was considered the backbone of any country.

Healthcare infrastructure is not something that should come to the limelight during an outbreak like Corona. A longterm action, regarding the overall development of healthcare infrastructure, should be the priority. The frontline healthcare workers are to be provided with

40 | September 2020

www.insightssuccess.com

Tech View

URING HCARE UITY

infrastructural facilities so that they can do their part. It now makes sense that the need for healthcare leaders and providers are growing. The requirement for professionals to manage healthcare facilities will also grow.

Till now there were two phases up to 1998 till 2010, during which several hospitals were built. Then the health sector was considered too expensive. Furthermore, there was also a very relevant expansion of privatization. The end result has been that in Italy and in some other European countries, the improvement of hospitals was stopped. Awareness and preparedness need to be elaborated to build the healthcare environment. What is clear is that the decentralized health system has been an issue.

The future of healthcare is shaping along with healthcare technologies such as AI, robotics, and nanotechnology.

Healthcare leaders will have to embrace change in order to stay relevant in the coming years.

Hence, we can conclude that the importance of the health facility systems and hospitals should be given priority.

Healthcare leaders are making miracles in adapting to the dramatic complexities of any situation. This is only a shortlist of continuous and constant management. This way, we would respect the healthcare leaders.

www.insightssuccess.com

September 2020 | 41

The 10 Most In luential Leaders in MedTech Companies, 2020

‘‘

Pharmaceutical services consulting and software

Jan Miotto President Metrendalytics

development company, focused on helping both pharma and CRO's

centralize operational data for real-time use.

44 | September 2020

www.insightssuccess.com

METRENDALYTICS Combining Knowledge and Technology to Bring Efficiency in Business

M

etrendalytics was founded by scientists, for scientists. Our goal is to provide integrated solutions which provide a consolidated view of all of one's operational data—whatever the source—on one shared platform for faster interactive collaboration and client service with reduced risk.

Metrendalytics recognizes that companies need a platform to create comprehensive efficiencies across project planning and execution with built-in analytic tools that are easy to implement, are highly customizable, and cost-effective. To enable this transformation journey to optimize “running the laboratory business” with technology requires innovative business solutions uniquely designed and customized around a company's specific business model and processes.

Metrendalytics works to understand and build systems to meet the unique process needs of each company. Then we enhance the resultant process efficiency with corresponding operational dashboard views with automated data integration, aggregation, and signal detection in interactive visualizations, which allows for centralized views and remote monitoring of project performance in real-time.

Reviewers are able to zero in on signals and trends that could affect operational performance and make smarter decisions sooner about how to deploy resources. This eliminates error prone, redundant entry and information update lag time associated with typical business management via various spreadsheets used for tracking of these activities which are a basis of vast inefficiencies. As a result, companies are essentially road blocked in the ability to unleash the power buried in their operational data.

Metrendalytics' solutions have been presented at multiple pharma/biotech meetings and conferences over the years.

Many of these presentations were from its customers. Most recently, it was featured in a Bioanalysis Zone article on how Metrendalytics' remote access solutions helped businesses continue and thrive through the Covid-19 pandemic.

Extensive Service Offerings

www.insightssuccess.com

Metrendalytics is a Pharmaceutical consulting services and software development company focused on helping pharma/biotech clinical operations and CRO's laboratory operations centralize operational data for real-time use. The company utilizes cloud-based, scalable, modular, rapid development, and low-cost platforms which are analytics and visualization enabled. The key to success is its software combines existing internal and external data into a single platform allowing customers to gain efficiencies and make faster, more informed decisions. As a result, the firm helps transition a business from a process that is reactive to one that is more proactive.

The laboratory tools and technologies in the bioanalytical laboratory have evolved and changed. However, leveraging real-time business data to make more informed decisions has seen limited progress. Further, additional time is required to manually create plots and metric reports to be used for analytics and process improvement initiatives. As a result, less time is available for analyzing data to improve business outcomes, customer service, and risk reduction.

Metrendalytics' software integrates the information from existing software like Salesforce, Watson, NetSuite, etc and incorporates these into a suite of applications to centralize from proposal creation, award, and management of milestones and deliverables through QC, QA, and reporting.

This provides a “one-stop-shop” for all critical business functions and data so that each stakeholder has what they need to efficiently complete their part. This means laboratory and management personnel can spend more time doing science and serving customers instead of chasing data and re-entering information.

Passion and Expertise Jan Miotto, President of Metrendalytics, had a successful career in the drug development industry because of her ethics of hard work and wanting to make things better for the industry. This, along with a lifelong passion to learn and apply new technologies is what drives the success of Metrendalytics. She has assembled a group of like-minded successful individuals who work together with the goal of making customers successful.

September 2020 | 45

Jan focuses on being authentic and bringing value every day and trying her best not to keep a fixed mindset in order to be able to explore new opportunities. Jan says, “If you wait for things to be perfect, you can miss opportunities.” She brings a mindset to never stop adapting. For Metrendalytics, experimentation has helped them reach a product-market fit.

Driving Improvement by Knowing Your Customer Metrendalytics' culture is to really partner with its clients to help take them to the next level. “We work with our customers to understand their business, their pain points, and where they want to be in the future,” says Jan. Being knowledgeable in the industry allows the company to understand each client's specific situation and allowing it to be flexible to design the tools they need to be successful. The goal is to add value and transparency to all levels of the organization.

Metrendalytics aims to improve the “life of the scientist in the laboratory” by providing tools to leverage already existing information. It helps mid-level managers drive improvement gains through automated capture of metrics and trends. It also provides senior-level executives up to the minute visibility to their entire portfolio to understand the current status of their projects and where action is needed to keep programs on track. By being more efficient with information, the company helps all levels of the organization perform better to help take time and cost out of the drug development process.

Current Crisis and Future Opportunities Metrendalytics has always been at the forefront when it comes to how it uses the information to improve business results. It will continue to do so in the future. The recent Covid-19 pandemic has accelerated the adoption of cloud-based and remotely accessed information systems. The company will build on its past success in this area to develop new and expanded

46 | September 2020

www.insightssuccess.com

capabilities to meet the full-service needs of its customers.

The company asserts “Our low cost, rapid development model also makes replacing some of the disconnected and more expensive “point solution” systems possible.”

Metrendalytics continues to build a network of experienced, results-oriented subject matter experts in the laboratory, drug metabolism, and chemistry manufacturing and controls. This expanded knowledge base provides access to new markets and the opportunity to leverage its technology to benefit these areas.

Socially Responsible Metrendalytics is active in Corporate Social Responsibility including philanthropy, environment conservation, diversity and labor practices, and volunteerism. As a company, Metrendalytics is diverse and designated as a femaleowned, minority business and some of its partners are also minority-based.

It has donated time and resources to start-up groups and technology companies that share the same passion for data and using that data to build the next-generation laboratory or improving upon existing technology to help the day-today work life of the scientist.

On Drug Development Challenges Drug development is a long and costly process typically requiring approximately 10 years and hundreds of millions of dollars. By developing solutions that reduce this time and cost, Metrendalytics not only saves money for customers but also helps get products to market faster. As a result, the public has access to potentially life-saving medications sooner. This in turn provides a revenue stream for the pharma company to reinvest in future drug development.

For CROs, where the name of the game is efficiency and value, here again, Metrendalytics helps to improve both of these. The more efficient the resources are in a CRO, the more projects can be completed, which accelerates drug development as noted above. It also means better profitability and stability for the CRO. For both CROs and pharma biotech companies, the time saved translates to more focus on the actual work of drug development instead of time wasted collecting and managing information. That time saved can then channelled into value-added activities like quality control, assessment and impact analysis or actions or innovations to improve the outcome.

Testimonials from Clients “Jan and her team at Metrendalytics collaborated with our www.insightssuccess.com

team at Alturas Analytics to create a total customized information management system that organizes and manages client information, data and resource management. The system has improved productivity, efficiency and compliance in our bioanalytical CRO. Thank you Metrendalytics!”

-Shane Needham, Co-Founder and Chief Scientific Officer at Alturas Analytics, Inc. “Immunologix Labs is accelerating our bioanalytical service delivery to the technology forefront with the Metrendalytics initiative. The platform will be our primary driver for industry-leading efficiency, organization and client experience. It will provide the architecture to seamlessly ensure consistent, high-quality, on-time performance for our clients. We are very enthusiastic about our partnership with Jahanara (Jan) Miotto and the team at Metrendalytics" -Michael Anderson, President and Chief Executive Officer at Immunologix Laboratories “We are on an exciting journey with Metrendalytics in moving from a paper heavy lab to a paper-lite lab to a paperless lab, which will enhance the efficiency of the entire laboratory process, leading to a dramatic overall cost reduction in operations and a better way to work for everyone. Many thanks to Metrendalytics in bringing our vision into reality” -Luca C Matassa, VP and Head of Bioanalytical at QPS Laboratoriese operational data for real-time use”

September 2020 | 47

The 10 Most In luential Leaders in MedTech Companies, 2020

Triox Na

Pioneers in point of care programmable medicine! presenting th

I

n an interview with Insights Success, Triox Nano's management describes its impeccable journey to become the first biotech company to develop a modular programmed drug delivery platform. The company's revolutionary technology, termed S.M.A.R.T, an acronym for Stimuli Multi Adjusted Responsive Technology, or simply put “Programmable medicine” is based on combinations of DNA coding, DNA molecular machines and mesoporous nanoparticles. SMART offers the potential to add programming to almost any approved medicine that may in turn increase its efficacy exponentially.

Prominent opinion leaders and investors had been funding TrioxNano's development to date including the European commission through the prestigious H2020 Horizon program. Competing with over 1500 companies TrioxNano's technology won a non diluting grant of roughly $2.5 million USD. TrioxNano's all inclusive patents are granted around the world . Many believe this breakthrough technology may lead the way to the next healthcare revolution!

To create S.M.A.R.T Triox Nano had to first invent the modular hardware that will allow incorporation of many different medications, the software language which is based on DNA coding and the actual codes that will control the nano particle. The technology is expected to create a paradigm shift and highly impact human lives around the globe, transforming medicine from its current primitive analog state to a programmable digital modern era.

S.M.A.R.T creates a vast field of programmable nanoparticles that can deliver their payload to target tissues based on the software code that is uploaded to them. The final commercialized product is expected to be supplied with a list of common software codes. The treating physician will decide which codes to use and will easily upload them to the modular nanoparticle that incorporates the relevant medication. The doctor will have the option to

48 | September 2020

upload a mixture of several codes into the same treatment based on the patient's clinical and pathologic profile.

Under the supervision of Joseph Farfara, Triox Nano's CEO, the company has progressed robustly in the last 3 years, broadening the type of medications that can be loaded into the platform, improving the capping characteristics and securing its IP with patents granted around the world.

Below are the highlights of the interview: Can you explain to our readers what so exciting about Triox Nano work?

Joseph Farfara, Triox Nano's CEO “By the year 2020, thousands of APIs (Active Pharmaceutical Ingredients) had been developed to treat different diseases, yet not even one efficient modular technology was developed to deliver them accurately to their target! The most efficient way to do this is use programming abilities so that each API can have tens of programs to direct it to different targets upon request. If you compare this to the car industry its like everyone has been developing thousands of types of engines without finding a way to connect them to the wheels yet. Current delivery methods, such as Injections or tablets deliver only a small percentage of their original doses to the tissues requiring treatment, and instead, most of the dose arrives to healthy tissue causing severe toxicity.

Examples for our programing abilities include the TXN770 family of nanoparticles intended for the treatment of TNBC (Triple Negative Breast Cancer). TXN770 combines between a modular unit loaded with the chemotherapy doxorubicin, that is already approved for the treatment of TNBC and the ability to be programmed by a combination of different software codes that control its release according to common traits found in the patient's specific tumor such as high levels of Magnesium and high levels of ATP. Other programing options we are developing include high levels

www.insightssuccess.com

ano

he next healthcare revolution! of PD1, PARP and Nucleolin found to be high in subgroups of TNBC patients. This allows us to use the same modular particle that includes Doxorubicin and program it to react to different cancer traits. In parallel we have created other modular particle loaded with the chemotherapies Mitoxantrone and Docetaxel (that is approved already for TNBC) that can use the same software codes described above (Mg, ATP, PD1, PARP, Nucleolin).

We are focusing on TNBC Triple Negative Breast Cancer to prove our technology's benefits but expect it to be relevant for many other indications. We offer specific licenses to the use of our S.M.A.R.T platform loaded with the client's APIs (active pharmaceutical ingredient). This is relevant for many types of companies, those who have a medication that is effective but proven to be too toxic to be used, or for medications that require high doses to be effective, or in cases patent cliff issues have to be avoided.

Our standard license agreements includes milestone payments and royalties fees, we offer our services for a fee to develop the asset until completion of the of In Vitro phase, expecting the companies to complete the In Vivo Tox and clinical trials.

What led to the inception of Triox Nano?

Answer Dr. Roy Farfara CTO and founder of TrioxNano The inception of TrioxNano was at 2 AM after a long operation of a young kidney cancer patient. Our department was regularly accepting patients that other surgeons had given up on operating them due to the technical difficulties.

We had the best techniques and technologies in Israel at the time (biologic glues, mannitol, hypothermia) we were taking out carefully tumor after tumor in the renal. We finished the surgery exhausted though we knew we did the best that can possibly be done. The patient kidney was not resected, we managed to take out all tumors and substantial bleeding avoided. Yet we understood that the patient ended

www.insightssuccess.com

Roy Farfara, MD Founder & CTO

September 2020 | 49

“Triox Nano’s technology offers a paradigm shift that will highly impact human lives, transforming medicine from an analog state to an exciting programmable digital modern era”

up having less than %20 of the original kidney parenchyma meaning he would most probably need dialysis in the near future. My grandfather Simon Farfara RIP who was an artisan taught me when I was a child that "The first step in every challenge is to find the best tools to complete it".

Understanding that it is not possible that in the year 2013 we are trying to resect micron (one millionths of a meter) size cancer cells with centimeter size knifes while on the other hand treating with chemotherapy that is not specific enough thus causing substantial side effects. Being aware of the limitation of surgery (trying to resect micro meter size cancer cells with inch size knifes) and the limitations of non specific chemotherapies causing substantial toxicity made me understand at that moment that we are totally not using the right tools to achieve this goal, and set me out on this journey” Describe Triox Nano and its cutting-edge technology.

Answer Dr. Ehud Saas head of biologic programming Interestingly computers have been incorporated into everyaspect of our lives except medicine. TrioxNano has developed and patented a programmable nano delivery platform that can carry different medications, including chemotherapies, to their target tissue. The technology uses nanoparticles based on DNA machinery. These amazing machines are made from single-stranded DNA and RNA and allow us to program a modular particle with almost infinite possibilities. Once completed, the technology will enable the treating physician to upload the relevant DNA module per individual patient and precise the administered treatment based on his specific cancer traits. It is estimated that more than 1000 approved medication can be delivered by this programmable system and at least 500 unique programmed modules can be uploaded to them. This adds up to about half a million different options of unique treatments (in the case that only one code is uploaded per particle), in the case a combination of three codes is loaded and estimated 125 billion treatment options are created.

As a leading pharma and biotech solution providers, what contribution has been made by you?

Answer by Dr. Ofer Nusbaum head of chemistry biology interface.

50 | September 2020

TrioxNano is trying to create a paradigm shift in the way we treat disease. Programming is urgently need to enhance the treatment of patients. In the case of Cancer as an example, cancer cells develop different mutations in different organs of the same patient. On the other hand different cancer type share common pathways. For example the PD1 pathway is relevant for a small percentage of TNBC patients and larger percentage in many other cancer types, many are being treated with PD1 inhibitors. This translate into a need for modular programmed platform that can relate to common traits in different tumors and different mutation in the same patient. We believe we will be able to offer the world the first modular programmable nano delivery platform where the physician will be able to program the medicine he gives his patient, he will choose from a list of software codes that we will offer commercialy and upload it to an armantarium of medication he can choose from. Later on we plan to offer specific programming to less common cases that require specific softwares. Of note is that all the different chemotherapies are packed in the same modular nanoparticle.

Describe in brief about the work culture and the values that drive Triox Nano.

Joseph Farfara, Triox Nano's CEO TrioxNano is driven by a team of highly intelligent hard working open minded scientist. All our staff have hands on experience of years in the industry. We are roughly divided to chemists and biologists that are integrators able to bridge the gap between these two worlds. As an Israeli company we try to think out the box and “cut to chase” as much as possible basing our decision on sound science.

What are the future aspirations of Triox Nano? What strategies are you undertaking to achieve those goals?

Answer Dr. Roy Farfara CTO and founder of TrioxNano TrioxNano aspires to be the next Microsoft and IBM, on one hand creating "the operating system for computerized drug delivery" and on the other developing the hardware required to run the operation system and the code. We want to revolutionize the way patients are treated! To achieve this

www.insightssuccess.com

goal our strategies include a hybrid business model where we develop our own drug candidate TXN770 (as a proof of concept) for the treatment of TNBC but are actively persuing to cooperate with others to incorporate their APIs (Active Pharmaceutical Ingredients) into our modular computerized platform.

IP and an exponential increase in value. This cooperation will importantly benefit humanity as thousands of medications can be improved which translate into improving human lifes!

How are you solving your customers' complex drug discovery challenges?

Joseph Farfara, Triox Nano's CEO

Answer Dr. Roy Farfara CTO and founder of TrioxNano By incorporating their APIs into TrioxNano's S.M.A.R.T platform, our partners may be able to increase efficacy while using smaller doses, creating decreased toxicity, new

What is your idea of Corporate Social Responsibility?

The hebrew saying "KOL HAMEZIL NEFESH ACHAT KEILU HEZIL OLAM U MELO'O," meaning he who saves one life is considered to save the world entire. www.Smartriox.com Joseph@TrioxNano.com

“It is estimated that more than 1000 approved medication can be delivered by this programmable system and at least 500 unique programs can be uploaded to them.

This adds up to about half a million different options of unique treatments (in the case that only one code is uploaded per particle), in the case a combination of three codes is loaded and estimated 125 billion treatment options are created."

www.insightssuccess.com

September 2020 | 51